TSXV:LBL.H - Post by User
Post by
laroplexon Feb 20, 2016 11:18am
219 Views
Post# 24577821
CEO's new "News and Updates"
CEO's new "News and Updates".
Hey BeattieB welcome to Lattice......Give them a call, they will answer all of your question....ALSO take a look again at the insider buying from Mario Stifano, small amount but he is constantly buying dribs and drabs on the Open Market.......Nonetheless a "Very good sign of Confidence"......GLTA
.
| Latest 10 SEDI filings (by transaction date) for LBL within the last 6 months | ? |
 Amended Filing |
| | As of 11:59pm ET February 19th, 2016 |
Filing
Date | Transaction
Date | Insider Name | Ownership
Type | Securities | Nature of transaction | Volume or Value | Price |
| Feb 19/16 | Feb 19/16 | Stifano, Mario | Direct Ownership | Common Shares | 10 - Acquisition in the public market | 1,000 | $0.245 |
| Feb 18/16 | Feb 18/16 | Stifano, Mario | Direct Ownership | Common Shares | 10 - Acquisition in the public market | 400 | $0.275 |
| Feb 17/16 | Feb 17/16 | Stifano, Mario | Direct Ownership | Common Shares | 10 - Acquisition in the public market | 2,000 | $0.275 |
| Feb 12/16 | Feb 12/16 | Stifano, Mario | Direct Ownership | Common Shares | 10 - Acquisition in the public market | 1,000 | $0.275 |
| Jan 26/16 | Jan 26/16 | Stifano, Mario | Direct Ownership | Common Shares | 10 - Acquisition in the public market | 2,000 | $0.290 |
| Jan 12/16 | Jan 12/16 | Stifano, Mario | Direct Ownership | Common Shares | 10 - Acquisition in the public market | 2,000 | $0.330 |
| Progress continues full-speed-ahead at Lattice these days. Enjoy the latest news and reports from our team. "Lattice Biologics (TSXV-LBL) building on biotech success one block at a time" Columnist Gaalen Engen dives into the technology and strategy behind the company that are getting Lattice noticed as a solid investment opportunity and reveals "The company's next generation proprietary patented Extracellular Matrix (ECM) solutions are set to revolutionize the regenerative medicine space." Milla Zakharova, Ph.D. Get to know one of our newest team members, Dr. Milla Zakharova, Senior Research Scientist in this issue's "Get to Know the Team Behind the Technology" feature. (Hint: this Ph.D. carries a "James Bond" style fun fact you won't want to miss.) INDUSTRY EVENTS: WSCS 2015: The Lattice team recently attended the World Stem Cell Summit in Atlanta, GA with over 1,200 fellow attendees including industry leaders, scientists, policymakers, and investors from 45+ countries. Get our official report here Join us next week in Park City, UT for the Spine event of the season. Details below. If you enjoy these newsletters, please share them with your friends and colleagues. As always, we appreciate your support on this journey! Sincerely, Guy Cook, CEO Lattice Biologics Ltd. | | Happy belated Valentine's Day from Lattice Biologics. Here's hoping you spent the day with your ideal "bond" this year! | Lattice in the News  | | NEW EDITORIAL HITS THE PRESSES "Lattice Biologics (TSX-V:LBL) building on biotech success one block at a time" "... This is where Lattice Biologics comes in. The company has developed a range of products based on its ground-breaking ECM solutions from traditional allografts such as bone dowels to soft tissue allografts used in tendon repair. Currently the competition only offers temporary tissue 'void fillers' that do nothing to promote healing or guide the cellular regeneration at the wound/surgical site. Instead, they leave the healing process up to the patient's stem cells, which as we get older, become less and less effective.
Lattice offers a directed scaffold technology derived from native ECM secreted by human Mesenchymal Stem Cells (hMSC). Enhanced for optimal regeneration, differentiation, homing and engraftment, Lattice's next generation ECM-based allografts dramatically improve the healing capacity while reducing surgical recovery times."
"This makes Lattice a pretty solid ticket as is, especially if it carries out some tasty acquisitions in regards to distribution, but if the company is able to get regulatory approval on its next generation of products within the next 12 to 18 months, the near-term growth potential on this will skyrocket. As well, although this is in early-stage R&D, the company is also working on a cutting-edge cancer diagnostics solution that, in future, could diversify its portfolio and add significantly to its bottom line." Read the live article here. | Meet the Team | Dr. Milla Zakharova Senior Research Scientist What do you most want to accomplish through your work at Lattice?
I'm committed to propelling this company towards becoming an industry leader in introducing the next generation of stem cell-based regenerative therapeutic products. Accomplishments:
My cardiac stem cell research at Banner Health's Center for Cardiovascular Research served as an IND (Investigational New Drug)-enabling study that allowed our team to secure $2.5M in funding to develop new stem cell-based therapeutic product for heart failure patients.
| Recent Industry Events | 2015 WSCS (World Stem Cell Summit) Conference Lattice Biologics Ltd. joined throngs of biotech specialists,manufacturers, inventors and investors at the Georgia International Convention Center for the Genetics Policy Institute (GPI) and the Regenerative Medicine Foundation (RMF)'s annual meeting. The event is described as "the most expansive interdisciplinary, networking meeting of stem cell science and regenerative medicine stakeholders, uniting the diverse community. With the overarching purpose of fostering biomedical research, funding and investments targeting cures, the Summit is the single conference charting the future of this burgeoning field." Lattice Biologics Ltd.'s resident Ph.D.s, Dr. Christopher Bradley and Dr. Milla Zakharova attended the event to represent our technologies and products, research the presentations, and collaborate with other regenerative medicine pioneers. | - Further Insights into the Complexity of the Extracellular Matrix
- Pluripotency and Differentiation
- Controlling Stem Cell Fate Using Multivalency and Optogenetics
-
Autologous vs. Allogeneic Cell Therapies -
From Tissue to Organs: 3D Bioprinting, Science and Industry Perspectives | Upcoming Events | | NORTH AMERICAN SPINE SOCIETY (NASS) 2016 Evidence & Technology Spine Summit Lattice will round out this month in Park City, UT at the NASS 12th Annual Evidence & Technology Spine Summit to "explore surgical and medical/interventional topics on the latest technology and techniques." | | Get the latest info on our newly trading TSX-V:LBL stock. For more information or assistance with how to buy, contact us. | | |